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Abstract
Background: The idiopathic inflammatory myopathies (IIM) are autoimmune diseases characterised by acquired
proximal muscle weakness, inflammatory cell infiltrates in muscle and myositis-specific/associated autoantibodies. It
is unclear which pathways are involved in IIM, and the functional relationship between autoantibody targets has
not been systematically explored. Protein-protein interaction and pathway analyses were conducted to identify
pathways relevant to disease, using autoantibody targets and gene products of IIM-associated single nucleotide
polymorphism (SNP) loci.
Methods: Protein-protein interactions were analysed using Disease Association Protein-Protein Link Evaluator (DAPPLE).
Gene ontology and pathway analyses were conducted using Database for Annotation Visualisation and Integrated
Discovery (DAVID) and Gene Relationships Across Implicated Loci (GRAIL). Analyses were undertaken including the
targets of published autoantibodies, significant and suggestive SNPs from an IIM association study and autoantibody
targets plus SNPs combined.
Results: The protein-protein interaction networks formed by autoantibody targets and associated SNPs showed
significant direct and/or indirect connectivity (p < 0.05). Autoantibody targets plus associated SNPs combined
resulted in more significant indirect and common interactor connectivity, suggesting autoantibody targets and
proteins encoded by IIM-associated loci may be involved in common pathways. Tumour necrosis factor
receptor-associated factor 6 (TRAF6) was identified as a hub protein, and UBE3B, HSPA1A, HSPA1B and PSMD3 also
were identified as genes with significant connectivity. Pathway analysis identified that autoantibody targets and
associated SNP regions are significantly interconnected (p < 0.01), and confirmed autoantibody target involvement in
translational and post-translational processes. ‘Ubiquitin’ was the only keyword strongly linking significant genes across
regions in all three GRAIL analyses of autoantibody targets and IIM-associated SNPs.
Conclusions: Autoantibody targets and IIM-associated loci show significant connectivity and inter-relatedness, and
identify several key genes and pathways in IIM pathogenesis, possibly mediated via the ubiquitination pathway.
Keywords: Idiopathic inflammatory myopathies, Autoantibodies, Association, Protein-protein interaction, Pathway analysis
* Correspondence: Janine.Lamb@manchester.ac.uk
†Equal contributors
1Centre for Epidemiology, University of Manchester, 2.722 Stopford Building,
Oxford Road, Manchester M13 9PT, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Parkes et al. Arthritis Research & Therapy  (2016) 18:156 
DOI 10.1186/s13075-016-1061-7
Background
The idiopathic inflammatory myopathies (IIM) are a group
of rare autoimmune diseases whereby patients typically
present with weakness and inflammation of skeletal muscle,
and extra-muscular manifestations including interstitial lung
disease, malignancy and skin rashes [1]. Approximately
80 % of patients with IIM possess serum autoantibodies;
these may be myositis-specific autoantibodies (MSAs),
which are found predominantly in IIM, or myositis-
associated autoantibodies (MAAs), which are found
also in other connective tissue diseases (CTD) or as part
of a myositis/CTD-overlap condition. MSAs are associ-
ated with a particular clinical profile and are usually mutu-
ally exclusive [1].
The most common MSA is anti-Jo-1 which is found
in about 20 % of patients with IIM. This MSA targets
histidyl tRNA synthetase, one of eight aminoacyl tRNA
synthetases (ARS) known to act as autoantigens for
MSAs [1]. Anti-ARS are associated with a distinct pheno-
type known as antisynthetase syndrome, which involves
myopathy, non-erosive arthritis, interstitial lung disease,
mechanic’s hands and fever [2].
Modification of the structure of an autoantigen, for
example, by somatic mutation or post-translational
modification, in a pro-immune context such as muscle
injury may result in an autoimmune response [2]. In
IIM, regenerating muscle cells produce higher levels of
autoantigens such as ARS molecules [3]. There is some
evidence that ARS molecules may act as chemoattrac-
tants inducing migration of immune cells to the affected
muscle [4]. Alongside elevated expression of major histo-
compatibility complex (MHC)-class I on cell surfaces, this
may lead to a specific autoimmune response resulting in
further muscle damage and regeneration; thereby more
autoantigen is produced, resulting in a sustained immune
response, disease propagation and amplification [2].
There are currently no disease-specific treatments for
IIM; instead anti-inflammatory, immunosuppressive
and immunodulatory treatments are borrowed from
other rheumatic diseases. Furthermore, despite treatment
some patients develop progressive muscle weakness and
extramuscular manifestions with ensuing disability and
poor quality of life. There is thus a clear need for new tar-
geted treatments in IIM. It is currently unclear which
pathways are involved in IIM and whether autoantibodies
contribute to the disease process. The functional relation-
ship between autoantibody targets has also not been sys-
tematically explored. Protein-protein interaction (PPI)
analyses have been performed in a number of complex
diseases, including breast cancer, schizophrenia and mul-
tiple sclerosis [5–8]. Genome-wide association studies
(GWAS) identify single nucleotide polymorphisms (SNPs)
associated with particular traits or diseases and PPI ana-
lyses have been used to identify the genes most likely to
be functionally significant to pathological change [6, 7];
the hypothesis is that associated genes will be involved in
a common set of biological pathways or processes, which
may be perturbed in the disease. It is possible that the tar-
geting of autoantigens in an autoimmune disease setting
like IIM also could be related to these altered pathways.
In this study we analysed PPI and pathways using auto-
antibody targets and proteins encoded by loci associated
with IIM in the largest genetic association study to date
[9], to identify pathways involved in IIM. This is the first
time a systematic PPI and pathway analysis has been
performed in IIM and suggests particular proteins and
pathways that may have important roles in disease.
Methods
Protein-protein interaction analysis
Analysis was performed using Disease Association Protein-
Protein Link Evaluator (DAPPLE) to investigate physical
connections between proteins [10]. DAPPLE searches the
InWeb database for PPI that have been reported in the
literature and assigned a probabilistic score. The InWeb
database compiles PPI data from numerous sources in-
cluding Reactome, IntAct, the Molecular Interaction
Database (MINT), the Biomolecular Interaction Network
Database (BIND) and the Kyoto Encyclopaedia of Genes
and Genomes (KEGG) [10]. DAPPLE is designed to ana-
lyse disease-associated single nucleotide polymorphisms
(SNPs) on the basis that disease-causing genetic variation
is likely to affect common pathways that may be revealed
by PPI [10].
Based on these interactions, DAPPLE forms networks
of physical protein-protein connectivity where proteins
are nodes connected by edges that represent interactions
in the InWeb database. A direct connection may be present
between two seed proteins (proteins derived from the input
SNPs or genes, also referred to as ‘associated proteins’) or
an indirect connection may be formed via a common inter-
actor protein (a protein not derived from the input but
which interacts with two or more seed proteins). Networks
between proteins are evaluated based on four parameters:
(1) number of direct interactions (number of edges in
the direct network); (2) mean associated protein direct
connectivity (the average number of proteins with which
each seed protein directly interacts); (3) mean associated
protein indirect connectivity (the average number of pro-
teins with which each seed protein indirectly interacts);
(4) mean common interactor connectivity (the average
number of seed proteins bound by common interactor
proteins) (Fig. 1).
The statistical significance of each parameter is assessed
using 20,000 permutations, comparing the network
formed against networks created by randomly reassigning
proteins of the same binding degree as the protein in the
original network to each node (binding degree was defined
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as the total number of interactions a protein has according
to the InWeb database). In a random list of proteins any
connectivity could simply be a function of the binding de-
gree of each protein. This method controls for bias intro-
duced by the differing extent to which certain PPI have
been studied or behave in vitro.
DAPPLE accepts named genes or SNPs as input. From
SNP input genes are identified as those in linkage dis-
equilibrium (LD) (r2 > 0.5), extended to the closest re-
combination hotspots plus 50 kb. Protein products of
genes in associated loci are then scored based on their
participation in direct and indirect networks. These
scores are Bonferroni corrected for two tests if a protein
participates in both networks and further Bonferroni
corrected for the number of possible candidates in that
locus to identify the ‘genes to prioritise’ (pcorr < 0.05).
[10]. Analysis was performed using DAPPLE, version 2,
Hg18, and HapMap SNPs.
Pathway analyses
Parallel pathway and gene ontology analyses were con-
ducted using Gene Relationships Across Implicated Loci
(GRAIL) [11] and the Database for Annotation, Visualisa-
tion and Integrated Discovery (DAVID) [12, 13]. GRAIL
uses an automated text-based strategy to identify signifi-
cantly inter-related genes based on a list of disease- associ-
ated regions, and identifies the most likely candidate gene
in each region [11]. Candidate genes within each region
are selected based on a significance score for their rela-
tionships to genes in other associated regions, corrected
for multiple hypothesis testing for the number of genes in
the region. Candidate genes with uncorrected GRAIL text
scores (ptext < 0.2) are used to identify the top twenty high-
est scoring keywords based on the average frequency of
that term for candidate genes versus all genes. These key-
words must appear in at least 500 documents, be four or
more letters long and contain no numbers [11]. GRAIL
makes no assumptions about the phenotype being studied
or underlying pathways presumed to be relevant to the
disease. Analysis was conducted using gene size correction
and the October 2014 text database.
DAVID analysis was conducted using biological processes
from the Gene ontology consortium (GOTERM_BP_FAT)
and pathways from KEGG using DAVID version 6.7.
P values were Benjamini-Hochberg corrected for multiple
hypothesis testing.
Input for protein-protein interaction and pathway analyses
Analyses were performed using the following inputs: (1)
all published MSA targets and anti-PMScl-75/100 targets;
(2) the most significantly associated SNPs from each re-
gion from a recently reported IIM Immunochip associ-
ation study [9]; (3) the combination of SNPs and
autoantibody targets (Table 1; these data are also avail-
able in Additional file 1). Anti-PMScl-75/100 was
Fig. 1 Parameters used to evaluate direct and indirect networks produced by the Disease Association Protein-Protein Link Evaluator (DAPPLE).
Protein products of genes in associated loci are shown in colour and common interactor proteins in grey
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Table 1 Myositis-specific and associated autoantibody targets and significant or suggestive SNPs used in analyses
Autoantibody targets (n = 28) SNPs (n = 22)
Symbol Description MSA/MAA rsID Coordinates (GRCh37 assembly) Immunochip p value [9] Clinical group
GARS Glycyl-tRNA synthetase Anti-EJ rs5754467 Chr22:21985094 4.67 × 10-07 IIM
YARS Tyrosyl-tRNA synthetase Anti-Ha rs6599390 Chr4:956047 6.48 × 10-07 IIM
HARS Histidyl-tRNA synthetase Anti-Jo-1 rs4853540 Chr2:191917317 1.57 × 10-06 IIM
NARS Asparaginyl-tRNA synthetase Anti-KS rs10189330 Chr2:99389870 2.68 × 10-06 IIM
IARS Isoleucyl-tRNA synthetase Anti-OJ rs570676 Chr11:36492191 9.42 × 10-06 IIM
AARS Alanyl-tRNA synthetase Anti-PL-12 rs223900 Chr16:57445376 9.97 × 10-06 IIM
TARS Threonyl-tRNA synthetase Anti-PL-7 rs451375
(Proxy for rs376072)
Chr3:28049889 (1.45 × 10-05) IIM
FARSA Phenylalanyl-tRNA synthetase,
alpha subunit
Anti-Zo-α rs3116494 Chr2:204592021 1.54 × 10-05 IIM
FARSB Phenylalanyl-tRNA synthetase,
beta subunit
Anti-Zo-β rs11064180 Chr12:6523249 1.61 × 10-05 IIM
CHD3 Chromodomain helicase DNA
binding protein 3
Anti-Mi-2α rs2476601 Chr1:114377568 7.22 × 10-09/7.90 × 10-11 IIM/PM
CHD4a Chromodomain helicase DNA
binding protein 4
Anti-Mi-2β rs3094013 Chr6:31434366 6.36 × 10-76 PM
SRP54 Signal recognition particle
54 kDa
Anti-SRP rs9905921 Chr17:71527243 2.01 × 10-06 PM
SAE1 Small ubiquitin related modifier 1
activating enzyme subunit 1
Anti-SAE-1 rs7956536 Chr12:109980516 3.66 × 10-06 PM
UBA2 Ubiquitin-like modifier activating
enzyme 2
Anti-SAE-2 rs2286896 Chr2:191535576 3.76 × 10-06 PM
TRIM33 Tripartite motif containing 33 Anti-TIF1γ rs17799348 Chr8:11333521 4.13 × 10-06 PM
TRIM24 Tripartite motif containing 24 Anti-TIF1α rs917998
(Proxy for rs1420095)
Chr2:103068156 (6.16 × 10-06) PM
TRIM28 Tripartite motif containing 28 Anti-TIF1β rs4690220
(Proxy rs11724804 in GRAIL)
Chr4:980464 7.47 × 10-06 PM
IFIH1 Interferon induced with helicase
C domain 1
Anti-MDA5 rs7535818
(Proxy rs2984920 in GRAIL)
Chr1:192545099 1.37 × 10-05 PM
NT5C1A 5'-nucleotidase, cytosolic 1A Anti-NT5C1A rs3129927 Chr6:32333827 3.74 × 10-48/2.06 × 10-129 DM/JDM/IIM
ABTB1 Ankyrin repeat and BTB (POZ)
domain containing 1
Anti-Fer rs4702698 Chr5:10517908 4.77 × 10-06 DM/JDM
HMGCR 3-hydroxy-3-methylglutaryl-CoA
reductase
Anti-HMGCR rs4921293 Chr5:159928876 8.27 × 10-06 DM/JDM
MORC3 MORC family CW-type zinc
finger 3
Anti-NXP2 rs1008723 Chr17:38066267 9.05 × 10-06 DM/JDM
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Table 1 Myositis-specific and associated autoantibody targets and significant or suggestive SNPs used in analyses (Continued)
PMS1 Postmeiotic segregation
increased 1
Anti-PMS1
PMS2 Postmeiotic segregation
increased 2
Anti-PMS2
MLH1 MutL homolog 1 Anti-MLH1
PRKDC Protein kinase, DNA-activated,
catalytic polypeptide
Anti-DNA PKCS
EXOSC9 Exosome component 9 Anti-PMScl-75
EXOSC10 Exosome component 10 Anti-PMScl-100
Single nucleotide polymorphisms (SNPs) were included if they reached the suggestive significance threshold (p < 2.25 × 10-5) for association with idiopathic inflammatory myopathies (IIM) in the Immunochip study
published by Rothwell et al., 2015. Subset of autoantibody targets used in Disease Association Protein-Protein Link Evaluator (DAPPLE) formed by selecting one protein from each complex are shown in bold (n = 21).
Subset of SNPs used in Gene Relationships Across Implicated Loci (GRAIL) analysis due to overlapping regions also shown in bold (n = 19) and proxies used for unrecognised SNPs are in brackets. aCHD4 also not
included in GRAIL analysis due to overlapping regions (autoantibody targets = 27). Clinical groups included polymyositis (PM), adult/juvenile dermatomyositis (DM/JDM) and all sub-groups combined (IIM)
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included despite being classified as an MAA, as it is al-
most always mutually exclusive to other MSA/MAAs.
The Uniprot IDs of all published MSA and anti-
PMScl-75/100 targets were identified (n = 28). SNPs
reaching GWAS thresholds for significance (p < 5 × 10-8)
or suggestive significance (p < 2.25 × 10-5, determined
using the genetic type I error calculator [14]) in the IIM
Immunochip association study [9] were identified from
each clinical subgroup (combined IIM, polymyositis,
adult/juvenile dermatomyositis) (n = 22). The genetic type
1 error calculator estimates the effective number of inde-
pendent tests based on the LD between SNPs contained
on the genotyping array. The most significantly associated
SNP was used for each region, or a proxy was used if this
SNP was not recognised by DAPPLE (proxy SNP in LD
r2 ≥ 0.9 with associated SNP, identified using SNAP ver-
sion 2.2, hg18, HapMap 22 [15]). Input genes (encoding
proteins that may participate in these networks) were
identified based on LD (r2 > 0.5 with the associated SNP)
and extension to the closest recombination hotspot for
GRAIL, or extension to the closest recombination hotspot
+50 kb for DAPPLE [10], resulting in 185 and 151 genes
used as input for GRAIL and DAPPLE, respectively. For
DAPPLE the analysis was also run using a subset of auto-
antibody targets selecting one protein from each complex
(n = 21), to remove bias from known interactions; this
subset was used in the combined autoantibody targets-
SNP analysis (n = 43). The genes from associated SNP
regions identified by DAPPLE were used as input for
DAVID; MHC region SNPs were excluded from the
DAVID analysis to remove bias introduced by the strong
LD and large number of immune-related genes across this
region, resulting in an input of 62 genes from 20 SNPs
plus the 28 autoantibody targets (n = 90).
Results
Protein-protein interaction analysis identifies significant
direct and indirect connectivity
The PPI networks formed by autoantibody targets and
IIM-associated SNPs using DAPPLE had significant direct
and/or indirect connectivity (pcorr < 0.05, Fig. 2, Additional
file 2), including when only one protein was selected from
Fig. 2 Protein-protein interaction analyses of associated single nucleotide polymorphism (SNP) loci and targets of myositis autoantibodies. a Direct
network for all SNPs of significant or suggestive significance (p < 2.25 × 10-5) reported in the idiopathic inflammatory myopathies (IIM) Immunochip
study. b Direct network for all SNPs of significant or suggestive significance and subset of myositis autoantibody targets (*one protein selected from
each complex). Colours indicate significance of node p value. c Summary statistics
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each known autoantibody target complex. These results
indicate that these proteins interact more than a group of
randomly selected proteins in 20,000 permutations of the
networks and therefore could be involved in common mo-
lecular networks linked to IIM. Due to strong direct PPI,
17/28 autoantibody targets were identified as genes to
prioritize as they participate in the network more than
would be expected by chance (pcorr values <0.05, Table 2).
SNP loci alone had significant indirect and common
interactor connectivity but direct connectivity was not
significant, suggesting that the proteins encoded by as-
sociated loci do not directly interact more than a ran-
domly selected group of proteins but may be involved
in common pathways (indirect networks and common
interactor p values may be found in Additional file 3).
The SNP analysis identified UBE3B (pcorr = 8.03 × 10
-4)
and TRAF6 (pcorr = 2.11 × 10
-3) as genes to prioritise.
Inclusion of both autoantibody targets and IIM-associated
SNPs resulted in greater and more significant indirect and
common interactor connectivity than either network
alone, suggesting indirect interaction between autoanti-
body targets and proteins encoded by IIM-associated loci
(Fig. 2b and c). Including both SNPs and MSA/MAA tar-
gets additionally identified PSMD3, HSPA1A and HSPA1B
alongside UBE3B and TRAF6 and seven myositis-specific
autoantibody (MSA) targets as genes to prioritise (Table 2).
From visual assessment of the direct networks tumour
necrosis factor receptor-associated factor 6 (TRAF6)
appears to act as a hub protein, interacting with many
proteins for both SNP and SNP-autoantibody target
networks (Fig. 2a and b).
Text-based pathway analysis of autoantibody targets and
associated SNP loci identifies significant inter-relatedness
GRAIL analysis identified 24/28 autoantibody targets as
significant based on their connections to the other auto-
antibody targets in the literature (pcorr < 0.01 for each auto-
antibody target). Only PRKDC, ABTB1, HMGCR and
NT5C1A were not significant (Additional file 4). The
twenty keywords identified by GRAIL confirmed previous
understanding of MSA target functions (‘tRNA’, ‘synthetase’)
and suggested autoantibody target involvement in post-
translational modification (‘sumoylation’, ‘ubiquitin’) (Additional
file 5). The VIZ-GRAIL (Visualising GRAIL connections) plot
showed strong connections (p<0.05), especially between the
anti-synthetase targets and within known complexes such as
CHD3-CHD4 and SAE1-UBA2 (Additional file 6).
In analysis of SNPs, only 4/19 regions were identified
as significant based on their connections to the other as-
sociated regions (pcorr < 0.01 for each candidate gene);
the most likely candidate genes STAT4, CD27, CCL17
and CD28 (Additional file 4). The majority of keywords
identified were immune-related, but also included ‘ubi-
quitin’ (Additional file 5). The VIZ-GRAIL plot showed
Table 2 Genes to prioritise from protein-protein interaction analyses of SNPs and targets of myositis-specific antibodies (MSA) or
myositis-associated autoantibodies (MAA)
All MSA/MAA targets (n = 28) Subset of MSA/MAA targetsa (n = 21) All SNPs (n = 22) All SNPs (n = 22) and subsets of MSA/MAA targetsa (n = 21)
Gene Pcorr value Gene Pcorr value Gene Pcorr value Gene Pcorr value
UBA2 3.03 × 10-4 GARS 3.16 × 10-4 UBE3B 8.03 × 10-4 TRAF6 3.01 × 10-4
GARS 5.05 × 10-4 PMS1 4.21 × 10-4 TRAF6 2.11 × 10-3 UBE3B 4.01 × 10-4
PMS1 3.63 × 10-3 UBA2 3.47 × 10-3 GARS 1.20 × 10-3
TRIM24 4.74 × 10-3 IARS 5.68 × 10-3 TARS 3.90 × 10-3
YARS 8.37 × 10-3 YARS 1.09 × 10-2 PSMD3 6.99 × 10-3
TRIM28 8.97 × 10-3 HARS 1.15 × 10-2 UBA2 1.19 × 10-2
NARS 9.17 × 10-3 AARS 1.78 × 10-2 PMS1 1.67 × 10-2
TRIM33 1.10 × 10-2 NARS 3.23 × 10-2 HSPA1B 2.73 × 10-2
IARS 1.15 × 10-2 YARS 3.79 × 10-2
MLH1 1.79 × 10-2 IARS 3.98 × 10-2
HARS 1.95 × 10-2 HARS 4.61 × 10-2
CHD3 2.67 × 10-2 HSPA1A 4.94 × 10-2
FARSA 3.02 × 10-2
AARS 3.10 × 10-2
TARS 3.23 × 10-2
EXOSC9 3.43 × 10-2
FARSB 4.61 × 10-2
Listed in order of significance from most to least significant. Pcor -values corrected for multiple testing.
aSubset of autoantibody targets formed by selecting one
protein from each complex.
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many strong pairwise connections between candidate
genes from associated loci such as C6orf21-GRB7, BLK-
STAT4, CD27-RAG2 and CD28-RAG1 (Fig. 3).
GRAIL analysis of SNPs and autoantibody targets com-
bined identified an increased number of autoantibody tar-
gets (25/27) and candidate genes (12/19) as significantly
interconnected to the other associated SNP regions or
autoantibody targets (pcorr < 0.01 for each autoantibody
target or candidate gene), suggesting inter-relatedness
between autoantibody targets and gene products of
IIM-associated loci (Additional files 4 and 7). Notably,
STAT1 was identified as the most likely candidate gene
in the combined analysis from the rs4853540 associ-
ation, rather than STAT4. Keywords included ‘ubiquitin’
and ‘sumoylation’ and immune and tRNA synthetase-
related terms (Additional file 6).
Gene ontology analyses confirm known pathways and
suggest novel pathways involved in IIM pathogenesis
DAVID gene ontology analysis of 28 autoantibody targets
confirmed previous knowledge of MSA target involvement
in translation and RNA metabolism, including amino acid
Fig. 3 Visualising Gene Relationships Across Implicated Loci (VIZ-GRAIL) plot of 19 associated single nucleotide polymorphism (SNP) loci. Outer
circle labelled with SNPs, inner circle with candidate genes. Thickness and brightness of lines represents the strength of the connections between
genes, VIZ-GRAIL (Visualising GRAIL connections)
Parkes et al. Arthritis Research & Therapy  (2016) 18:156 Page 8 of 13
activation (pcorr = 7.6 × 10
-12), tRNA aminoacylation
(pcorr = 7.6 × 10
-12), tRNA metabolic process (pcorr =
6.5 × 10-9), non-coding RNA metabolic process (pcorr =
2.1 × 10-9) and translation (pcorr = 8.5 × 10
-7) (Additional
files 8 and 9). Autoantibody targets were shown also to
be significantly involved in somatic recombination of
immunoglobulin gene segments (pcorr = 4.3 × 10
-2). The
only significant KEGG pathway was aminoacyl-tRNA
biosynthesis (pcorr = 9.8 × 10
-12), which is unsurprising
as nine of the autoantibody targets are aminoacyl tRNA
synthetases. Gene ontology analysis of the associated
SNP loci identified only immune response as significant
(pcorr = 0.015). Combined analyses of autoantibody targets
and associated SNP loci identified additional significant
immune-related gene ontologies such as somatic diversifi-
cation of immune receptors (pcorr = 2.9 × 10
-3).
Discussion
We report the first systematic protein-protein interaction
and pathway analysis of myositis autoantibody targets and
proteins encoded by IIM-associated loci [9]. Our analyses
identify significant direct and indirect connectivity and inter-
related genes/proteins. Several genes are highlighted by PPI
analysis including TRAF6, HSPA1A/B, UBE3B and PSMD3.
Pathway analysis confirmed the over-representation of auto-
antibody target involvement in translation and suggests that
ubiquitination may play an important role in the IIM disease
processes.
The significant direct and indirect connectivity identified
between autoantibody targets indicates physical interac-
tions between these antigens and with common interactors
and suggests related biological pathways. The significant
indirect connectivity between associated SNP loci suggests
that although proteins encoded by these loci do not dir-
ectly interact, they may influence common pathways, in
keeping with potential long-range regulatory effects. The
more significant indirect and common interactor connect-
ivity observed in the combined analysis suggests autoanti-
body targets and proteins encoded by IIM-associated loci
act in the same pathways.
The direct networks produced by DAPPLE suggest an
important role for TRAF6 interactions with both auto-
antibody targets and SNP-associated gene products in
IIM. TRAF6 is an E3 ligase which acts as an intermedi-
ate signalling adaptor between signals such as pathogen-
associated molecular patterns (PAMPs) and downstream
pathways including nuclear factor-kB (NF-kb), c-Jun
N-terminal kinase (JNK), mitogen-activated protein
kinase (MAPK) and AMP-activated protein kinase (AMPK).
TRAF6 is involved in immune responses via the regulation
of inflammation [16], differentiation and proliferation
of B cells [17] and development of medullary thymic
epithelial cells [18]. TRAF6 also is implicated in muscle
atrophy [19]. These roles support the hypothesis that
TRAF6 may have an important role within muscle as
part of the autoimmune, inflammatory process in IIM,
and TRAF6 with associated pathways may represent
potential therapeutic targets.
Of the seven autoantibody target-derived ‘genes to pri-
oritise’ in the DAPPLE analysis of SNPs and autoantibody
targets, five were aminoacyl tRNA synthetases (ARS). In
the direct network four of these (TARS, HARS, GARS
and YARS) directly interacted with TRAF6. Some of the
statistical significance of these proteins may be derived
from interactions within the ARS group. However, a
proportion will be due to their interaction with TRAF6.
Further study of these interactions may be valuable in
understanding the link between presence of anti-ARS
and the specific phenotype observed in anti-synthetase
syndrome.
A further ‘gene to prioritise’, UBE3B, is not present in
the direct networks, and derives significant connectivity
indirectly via common interactor proteins. UBE3B en-
codes ubiquitin protein ligase E3B, which is involved in
target recognition in the ubiquitination pathway. Another
‘gene to prioritise’, PSMD3, encodes a 26 s proteasome
regulatory subunit involved in degradation of ubiquiti-
nated proteins via the ubiquitin proteasome pathway
(UPP). In the Immunochip study two associations were
reported as intergenic of PRR5L/TRAF6 and UBE3B/
MMAB [9]. Our analyses could suggest TRAF6 and
UBE3B as the causal genes in their respective regions.
UBE2L3, an E2 ubiquitin-conjugating enzyme, was also
highlighted in the Immunochip study as it has previ-
ously been implicated in other autoimmune diseases.
Four of five prioritised SNP-derived genes identified in
the DAPPLE analyses encode proteins related to the
UPP (Fig. 4). Furthermore, ‘ubiquitin’ was the only key-
word identified in all three GRAIL analyses (Additional
file 6). In IIM, ubiquitination is involved in activation
of NF-kB which in turn leads to upregulation of MHC
class I, promotion of inflammatory cytokines leading to
muscle fibre damage, and MyoD inhibition resulting in
reduced myoblast differentiation (Fig. 4) [20].
The UPP is thought to be the most significant degrad-
ation system in myogenesis [21]. Inhibition or knock-
down of the proteasome prevents myoblast fusion and
inhibits differentiation, whereas proteasomal activity in-
creases during differentiation of mouse myoblast C212
cells [21] and has been found to be increased in IIM
muscle tissue [22].
In inclusion body myositis (IBM), abnormalities of
muscle protein homeostasis may lead to accumulation of
proteins in muscle fibres, possibly as a result of impaired
proteasome function. Gene mutations resulting in dis-
rupted ubiquitination have been identified in several
inherited myopathies such as nemaline and polyglucosan
body myopathy [23, 24].
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As illustrated by Fig. 4, enhanced proteasome activity
generates MHC class I restricted antigens, leading to ac-
tivation of the immune response. Stress-inducible heat
shock 70 kDa (Hsp70) proteins, such as HSPA1A and
HSPA1B, upregulated when cells are under stress, act as
chaperones for transferring these antigens from the pro-
teasome to be presented by MHC class I or II [25].
Hsp70 proteins play a critical role in protecting against
muscle damage in the innate immune response, promot-
ing muscle regeneration and recovery, and maintaining
skeletal muscle mass and integrity [26]. This response
decreases with increased age. As IIM is generally a dis-
ease of middle and old age it is thought that restoration
of the heat-shock response may be a good therapeutic
approach, especially in IBM where protein mishandling
is most clearly seen in the form of protein aggregates in
muscle fibres. Arimoclomol is a pharmacological agent
that induces an increased heat-shock response in stressed
cells but does not appear to affect unstressed cells, thus
avoiding off-target responses [27]. Arimoclomol has
shown promise in ameliorating disease in both in vitro
rat myoblast and in vivo mouse models of IBM and has
passed safety testing in IBM patients [27]. A further
pharmacological agent, 17-N-allylamino-17-demethoxy-
geldanamycin (17AAG), upregulates Hsp70. Treatment
with 17AAG has been shown to preserve mitochondrial
function and prevent atrophy of C2C12 mouse myo-
tubes in a tunicamycin-induced endoplasmic reticulum
Fig. 4 Proposed ubiquitin proteasome pathway (UPP) involvement in idiopathic inflammatory myopathies (IIM). Endoplasmic reticulum (ER) stress
leads to upregulation of the UPP. Ubiquitin binds to the E1 ubiquitin activating enzyme, which is then replaced by E2 ubiquitin conjugating enzyme. E3
ubiquitin ligase then brings in the target protein, in this example, inhibitor of nuclear factor kB (IkB), and catalyses repeated ligation to the ubiquitin. UBE3B
is an E3 ligase. The polyubiquitinated protein is targeted to the 26S proteasome (of which PSMD3 is a component) and degraded. Peptide fragments can
then be chaperoned by proteins such as HSPA1A/B to major histocompatibility complex (MHC) class I for presentation. The degradation of IkB results in
activation of NFkB, which promotes production of MHC class I and inflammatory cytokines and inhibits MyoD. MHC class I overexpression results in further
ER stress, MyoD inhibition results in reduced myoblast differentiation and inflammatory cytokines cause damage to muscle fibres
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(ER)-stress model of IIM [28]. This PPI analysis
highlighting heat-shock proteins in association with
IIM lends further support to targeting the heat shock
response in development of future IIM treatments.
A limitation of this study is that MSA/MAAs target
intracellular antigens and it is unclear whether the auto-
antibodies or the pathways in which the antigens are in-
volved influence the pathogenesis of IIM, and how these
antigens come to be exposed to the immune system in
IIM break of tolerance. The IIM-associated SNPs are
from an Immunochip study, therefore, the identification
of immune-related keywords is likely influenced by the
biased content of the Immunochip. However, these re-
sults are still informative and highlight non-immune
pathways that could be investigated as potential thera-
peutic targets in IIM.
Conclusions
In conclusion, through PPI and pathway analyses, this
study highlights several genes including TRAF6,
HSPA1A/B, UBE3B and PSMD3, and pathways including
ubiquitination, which may play important roles in IIM
disease processes.
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